Local advanced prostate cancer and M1 patterns are incurable, making quality of life the most important outcome. A Phase II study conducted by Bruchovsky suggests that intermittent therapy is an alternative way of improving quality of life without compromising survival.
Method
An international co-operative group, the South European Uro-oncological Group (SEUG), launched a Phase III trial comparing intermittent MAB with continuous MAB. The inclusion criteria were: histological-proven prostate cancer T3±T4; M0 and M1 patients; WHO 0±2; age`85 y; and previously untreated prostate cancer. All patients were registered and treated with CPA 200 mg for 2 weeks and then given a monthly depot injection of LH± RH analogue (Decapeptyl2) plus 20 mg CPA daily. After 3 months of therapy, patients were randomized if PSA was`4 or 80% of the initial value. The criteria response was the presence of two of the following parameters: increase of prostate-speci®c antigen (PSA) by 20%, or on two successive occasions, at least one month apart while on treatment; worsening of WHO performance status by two scores; or an increase in pain by two scores. Patients repeated therapy in the group below 4 when PSA was b 10 if symptomatic, or b 20 if unsymptomatic; in the group`80%, therapy was given when PSA increased by 20%.
To test the difference between continuous and intermittent blockage, it was assumed that the time to progression with MAB was approximately 133 weeks or 2.5 y in 60% of the patients and that overall survival at the same time was 30%. To show evidence of a treatment difference in time to progression of 30% (60±48), it was calculated that 270 patients were required for each treatment.
Results
A total 608 patients have been registered so far; 418 have been randomized, 133 are awaiting randomization and 57 do not meet the entry criteria. We will present the preliminary results of an analysis of 409 patients: 203 in the intermittent arm (135 M0, 61 M1 and 2 NA) and 206 in the continuous arm (132 M0, 71 M1 and 3 NA).
After 3 months of therapy PSA was, on average, down by 97%. At randomization, 23.7% of the patients had PSA in excess of 4 ng/ml and the rest (76.3%) had a PSÀ 4 ng/ml. In the intermittent arm 50% of patients discontinued therapy for at least 39 weeks following initiation of LH±RH CPA therapy, and 40% for over one year. Those who remained off therapy tended to have lower PSA at randomization. Intermittent patients who resumed therapy stayed on it for a medium of 17 weeks. Median PSA was slightly higher in the intermittent group, as would be expected. WHO and pain scores were the same for the two groups. Side-effects were low, the most common one being hot¯ushes, which was reported in 10% of patients. Quality of life seemed to be the same in the two arms.
For a medium follow-up of 18 months, we have included 43 patients out of 409 randomized in progression, 18 in the continuous arm and 25 in the intermittent arm. This means there are no signi®cant differences in progression rate between the two arms. Time to subjective progression is the same in both arms.
Conclusion
With a medium follow-up of 18 months, it is too early to assess progression and survival. However, there was no difference in quality of life and subjective progression between the two study arms. In addition, the preliminary ®ndings suggest that initial therapy can be given only for
